OPTI-HEP-D : a protocol for an intervention study comprising screening and linkage to care of people living with hepatitis D in Catalonia
Palom, Adriana (Hospital Universitari Vall d'Hebron)
Rando-Segura, Ariadna (Vall d'Hebron Institut de Recerca (VHIR))
Fernández, Gema (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Calatayud, Laura (Hospital Universitari de Bellvitge)
Sellés-Sánchez, Alicia (Hospital Universitari Joan XXIII de Tarragona)
Pérez del Campo, Dúnia (Hospital Universitari de Girona Doctor Josep Trueta)
Mormeneo Bayo, Saray (Hospital Arnau de Vilanova (Lleida, Catalunya))
Perez Moreno, Maria Mar Olga (Hospital de Tortosa Verge de la Cinta)
Tabernero, David (Vall d'Hebron Institut de Recerca (VHIR))
Ayats, Josefina (Institut Català de la Salut)
Llopis, Maria Antonia (Institut Català de la Salut)
Quer, Juan Carlos (Hospital Universitari Joan XXIII de Tarragona)
Buti, Maria (Hospital Universitari Vall d'Hebron)

Data:	2024
Resum:	Hepatitis B virus (HBV) affects 296 million people globally, causing 780 000 annual deaths. It has been estimated that 12-43 million individuals are co-infected with hepatitis D virus (HDV). In Spain, the prevalence of HBsAg in adults is 0. 22%, with an anti-HDV prevalence of 7. 7%, although not extensively documented since many HBsAg-positive cases are not tested for anti-HDV. The primary objective of this project is to optimise hepatitis D care by implementing a screening programme for anti-HDV in all HBsAg-positive individuals over a 1 year period in Catalonia. Secondary objectives include evaluating hepatitis D prevalence, establishing a digital registry for all anti-HDV positive cases, testing them for HDV-RNA in a centralised laboratory and offering linkage to care. This prospective study will be performed in seven hospital centres in Catalonia, which attend to more than 95% of the adult population. Approximately, 9290 HBsAg-positive individuals are expected to be screened for anti-HDV in 1 year. All anti-HDV positive samples will be sent to a centralised laboratory for HDV-RNA quantification. All individuals testing positive for anti-HDV will be registered on an electronic platform and linked to care. The registry will collect data on demographics, infection stage, risk factors, disease awareness and previous diagnoses. No additional interventions will be conducted for those with adequate follow-up. The Vall d'Hebron Hospital Ethics Committee (PR(AG)628/2023) and the Spanish Agency of Medicines and Medical Devices approved this study. These findings will be disseminated through peer-reviewed publications and conference presentations. Grant number: IN-ES-980-7058.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Hepatology ; Mass Screening ; Public health
Publicat a:	BMJ open, Vol. 14 (november 2024) , ISSN 2044-6055

DOI: 10.1136/bmjopen-2024-086961
PMID: 39581731

4 p, 697.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats